Midatech Pharma Plc EV/EBITDA
What is the EV/EBITDA of Midatech Pharma Plc?
The EV/EBITDA of Midatech Pharma Plc is 0.40
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with ev/ebitda similar to Midatech Pharma Plc
- Northern Bitcoin AG has EV/EBITDA of 0.39
- Jilin Province Huinan Changlong Bio-pharmacy has EV/EBITDA of 0.39
- Cassowary Capital has EV/EBITDA of 0.39
- SciPlay has EV/EBITDA of 0.40
- Mmtec has EV/EBITDA of 0.40
- Meat-Tech 3D Ltd has EV/EBITDA of 0.40
- Midatech Pharma Plc has EV/EBITDA of 0.40
- Teras Resources has EV/EBITDA of 0.40
- WestStar Industrial has EV/EBITDA of 0.40
- Gulfport has EV/EBITDA of 0.40
- SDX Plc has EV/EBITDA of 0.40
- Harpoon Therapeutics has EV/EBITDA of 0.41
- Litho Formas, S.A has EV/EBITDA of 0.41